PEDIATRICS Vol. 52 No. 5 November 1973, pp. 637-644
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, D. H.
Right arrow Articles by Anderson, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, D. H.
Right arrow Articles by Anderson, P.

RESPONSES OF CHILDREN IMMUNIZED WITH THE CAPSULAR POLYSACCHARIDE OF HEMOPHILUS INFLUENZAE, TYPE b

David H. Smith M.D.1, Georges Peter M.D.1, David L. Ingram M.D.1, A. Lynn Harding B.A.1, and Porter Anderson Ph.D.1

1 Division of Infectious Diseases, Children's Hospital Medical Center, Department of Pediatrics, Harvard Medical School, Boston Massachusetts

One hundred forty-one children of 5 to 59 months of age were immunized with a single intramuscular dose of 0.67, 3.3, 17, or 67µg polyribophosphate (PRP), the capsular antigen of Hemophilus influenzae, type b. The immunizations were well tolerated, particularly at doses of .67 to 17µg. Antibody activity was measured by radioactive antigen binding, using 3H-labelled PRP. Doses of 3.3 and 17µg produced significant antibody rises in nearly 90% of recipients; 0.67 and 67µg in approximately half. The geometric mean titers were similar at three and six weeks after immunization and were greater with the middle doses.

The net antibody increase in responding children was strongly age dependent, but was not related to the preimmunization antibody concentration. Rises in serum bactericidal activity against H. influenzae type b generally accompanied rises in antibody concentration as measured by the antigen-binding assay.

Submitted on March 21, 1973
Accepted on July 20, 1973




This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. Latz, J. Franko, D. T. Golenbock, and J. R. Schreiber
Haemophilus influenzae Type b-Outer Membrane Protein Complex Glycoconjugate Vaccine Induces Cytokine Production by Engaging Human Toll-Like Receptor 2 (TLR2) and Requires the Presence of TLR2 for Optimal Immunogenicity
J. Immunol., February 15, 2004; 172(4): 2431 - 2438.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Muthukkumar, J. Goldstein, and K. E. Stein
The Ability of B Cells and Dendritic Cells to Present Antigen Increases During Ontogeny
J. Immunol., November 1, 2000; 165(9): 4803 - 4813.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. Peter
Responses of Children Immunized with Capsular Polysaccharide of Hemophilus influenzae Type b, by David H. Smith, MD, et al, Pediatrics, 1973;52:637-644; and Haemophilus influenzae Type b Capsular Polysaccharide Vaccine in Children: A Double-blind Field Study of 100 000 Vaccinees 3 Months to 5 Years of Age in Finland, by Heikki Peltola, MD et al, Pediatrics, 1977;60:730-737
Pediatrics, July 1, 1998; 102(1): 252 - 254.
[Abstract] [Full Text]

Home page
 The Journal of the Royal Society for the Promotion of HealthHome page
A. K.C. Leung, A. S.K. Chiu, and T. O. Siu
Subcutaneous versus intramuscular administration of Haemophilus influenzae type b vaccine
The Journal of the Royal Society for the Promotion of Health, April 1, 1989; 109(2): 71 - 73.
[Abstract]